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ABSTRACT 
Background: 
Skin disorders have been associated with specific microbiome changes and 
raised an interest in developing new diagnostic methods and treatments. 
 
Objectives: 
To investigate the microbiome in skin cancer (melanoma, study I) and 
inflammatory skin disorders (parapsoriasis, study II), to explore microbiome 
swab sampling as a non-invasive diagnostic method, and to investigate the 
skin microbiome in very low birth weight infants in intensive care and possible 
association of skin staphylococci and neonatal sepsis (study III). 
 
Methods: 
Microbiome samples were taken of 15 cutaneous melanomas and 17 benign 
melanocytic nevi (study I), of parapsoriasis lesional skin and contralateral 
healthy skin in 13 patients (study II) and in 12 very low birth weight infants 
during treatment in intensive care (study III). 
Sequencing was carried out on 454 GS-FLX Titanium (study I) and 
Illumina MiSeq (studies II-III) platforms and the data was analysed by 
bioinformatics. In studies I-II alpha diversity indices were calculated with 
bioinformatic tools. In study II the staphylococcus sequences were 
investigated by oligotyping. 
 
Results: 
In study I there were no significant differences in the microbiome of 
melanomas, melanocytic nevi and controls. A notable interpersonal variation 
was observed. No significant differences in bacterial diversity could be 
detected. 
In study II the microbiome showed no significant differences between 
parapsoriasis and the same patient’s healthy looking skin. No differences 
could be demonstrated between small and large plaque parapsoriasis. Based 
on oligotyping Staphylococcus aureus was not identified in parapsoriasis skin. 
In study III a high cutaneous microbial diversity was observed in most 
infants at birth. There was a decrease in diversity during the first three weeks 
of life in both septic and non-septic infants. In 50 % of the infants the microbial 
diversity recovered. There was no association between microbiome changes 
and sepsis.  
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Conclusions: 
Study I was about the microbiome in melanomas and melanocytic nevi. There 
was a substantial variation between body sites and individual patients. The 
results suggest that microbiome swab sampling may not be helpful in 
diagnostics of melanoma or melanocytic nevi. Limitations were a small and 
heterogeneous patient group and possible bias in sampling and analysis. 
Study II was about the skin microbiome in parapsoriasis. No significant 
differences could be demonstrated between parapsoriasis and healthy skin.  
Recently it has been shown that Staphylococcal enterotoxin A from the 
affected skin of cutaneous lymphoma patients induced in vitro IL-17 
production in primary malignant T-cells of Sezary syndrome patients when 
cocultured with autologous nonmalignant T-cells. Parapsoriasis is known to 
precede mycosis fungoides, the most common form of cutaneous T-cell 
lymphoma. The role of staphylococci has, to our knowledge, not been 
investigated in parapsoriasis. We could not identify S. aureus in parapsoriasis 
lesions. This suggests that S. aureus and staphylococcal enterotoxins do not to 
play a role in parapsoriasis. Specific differences between cutaneous lymphoma 
and parapsoriasis or metabolomics may explain the observations. Limitations 
were a small patient group and notable interpersonal variations. 
Study III was about the skin microbiome in very low birth weight infants. 
A high microbial diversity was present during the first days of life regardless 
of the way of delivery, prematurity causes or perinatal infections. The diversity 
decreased during the first weeks of life possibly due to intensive care treatment 
and antibiotics. 
Neonatal sepsis showed no time-based link with the decrease of diversity 
and shifting into a staphylococci dominated microbiome. It is likely that other 
factors play a role, e.g. skin injury by medical devices and concomitant 
infections. Limitations were a small patient group and irregularly carried out 
sampling during intensive care. 
 
 
 
 
 
 
 10 
TIIVISTELM(ABSTRACT IN FINNISH)
Tausta: 
Ihosairauksissa todetut mikrobiomin muutokset ovat herättäneet kiinnostusta 
uusien diagnoosimenetelmien ja hoitomuotojen löytämiseksi. 
 
Tavoitteet: 
Väitöskirjan tavoitteena oli selvittää ihon mikrobiomi ihosyövässä 
(melanooma, tutkimus I) ja tulehduksellisissa ihosairauksissa (parapsoriasis, 
tutkimus II) sekä tutkia näissä ei-invasiivisen mikrobiomi pyyhkäisynäytteen 
käyttökelpoisuutta. Lisäksi tavoitteena oli kartoittaa ihon mikrobiomi erittäin 
alhaisen syntymäpainon keskosissa tehohoidossa ja sen mahdollista yhteyttä 
ihon stafylokokkeihin ja sepsikseen (tutkimus III). 
 
Menetelmät: 
Mikrobiominäytteitä otettiin 15 melanoomasta ja 17 hyvänlaatuisesta 
melanosyyttiluomesta (tutkimus I), 13 potilaan parapsoriasis ihomuutoksista 
sekä terveeltä iholta (tutkimus II) ja 12 erittäin alhaisen syntymäpainon 
keskosesta tehohoidon aikana (tutkimus III). 
Sekvensointi toteutettiin 454 GS-FLX Titanium (tutkimus I) ja Illumina 
MiSeq (tutkimukset II-III) alustoilla ja tietoja analysoitiin bioinformatiikan 
avulla. Tutkimuksissa I-II mikrobiomin diversiteetin indeksit laskettiin 
bioinformatiikan apuvälineillä. Tutkimuksessa II stafylokokkien sekvenssit 
tutkittiin tarkemmin käyttäen oligotyypitystä.  
 
Tulokset: 
Tutkimuksessa I ihon mikrobiomi oli samankaltainen melanoomissa ja 
hyvänlaatuisissa melanosyyttiluomissa. Näytteissä todettiin merkittävää 
yksilöllistä vaihtelua. Merkittäviä eroja bakteeriston diversiteetissä ei tullut 
esille melanoomien ja hyvänlaatuisten luomien välillä. 
Tutkimuksessa II ei todettu merkittäviä eroja mikrobiomissa parapsoriasis 
ihottuman ja terveen näköisen ihon välillä. Myöskään pientäpläisen ja 
suurtäpläisen parapsoriasiksen välillä ei todettu merkittäviä eroja. 
Staphylococcus aureus bakteeria ei havaittu oligotyypityksellä parapsoriasis 
ihottumassa. 
Tutkimuksessa III havaittiin useimmilla keskosilla syntyessä korkea ihon 
mikrobien diversiteetti. Kolmen ensimmäisen elinviikon aikana diversiteetti 
kaventui sekä septisillä että ei-septisillä keskosilla. 50 %:lla keskosista nähtiin 
diversiteetin elpyminen, mutta tämä ei ollut ajallisessa yhteydessä sepsikseen. 
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Johtopäätökset: 
Tutkimus I käsitteli ihon mikrobiomia melanoomassa ja 
melanosyyttiluomissa. Mikrobiomi vaihteli merkittävästi tutkitun ihoalueen 
ja yksittäisten potilaiden välillä. Löydöksemme viittaavat siihen, että 
mikrobiomin tutkimisesta ei ole hyötyä melanooman tai melanosyyttiluomien 
diagnostiikassa. Tutkimuksen rajoituksia olivat pieni ja heterogeeninen 
potilasryhmä sekä näytteenottoon ja analyysiin liittyvät metodiset ongelmat. 
Tutkimus II käsitteli ihon mikrobiomia parapsoriasiksessa. Mikrobiomin 
ei todettu eroavan merkittävästi terveestä ihosta. Vastikään on in vitro 
tutkimuksissa osoitettu, että stafylokokkien enterotoksiini A voi indusoida 
ihon lymfoomaa sairastavilla IL-17-tuotantoa Sezaryn syndrooman potilaiden 
primaarisissa pahanlaatuisissa t-soluissa, kun näitä viljeltiin autologisilla, ei-
maligneilla t-soluilla. Parapsoriaasiksen tiedetään edeltävän Mycosis 
fungoidesta, joka yleisin ihon t-solulymfooma. 
Stafylokokkien roolia ei ole tietääksemme tutkittu aikaisemmin 
parapsoriasiksessa. Tutkimuksessa emme havainneet S. aureus bakteeria 
parapsoriasis ihottumassa. Tämä viittaa siihen, että S. aureuksella tai sen 
enterotoksiineilla ei ole merkitystä parapsoriasiksessa. Iholymfoomien ja 
parapsoriasiksen selvät erot patogeneesissa ja metabolomiikka voivat selittää 
nämä tulokset. Tutkimuksen rajoituksia olivat pieni potilasryhmä ja ihon 
mikrobiomin merkittävät yksilölliset vaihtelut. 
Tutkimus III käsitteli erittäin alhaisten syntymäpainon keskosten ihon 
mikrobiomia. Pystyimme osoittamaan mikrobiomin korkean diversiteetin 
ensimmäisinä elinpäivinä riippumatta syntymistavasta, keskosuuden syystä 
tai infektioista. Diversiteetti kaventui ensimmäisen elinviikon aikana johtuen 
mahdollisesti tehohoidossa annetuista antibiooteista. 
Vastasyntyneiden sepsis ei ollut yhteydessä diversiteetin kaventumiseen 
eikä siihen, että mikrobiomia hallitsi tämän jälkeen stafylokokkikolonisaatio. 
Sepsiksen taustalla on luultavasti muita tekijöitä kuten ihoa lävistävät 
lääkinnälliset laitteet tai samanaikaiset infektiot. Tutkimuksen rajoitukset 
olivat pieni potilasryhmä ja ajallisesti epätasainen näytteenotto tehohoidossa.
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1 INTRODUCTION 
1.1 THE SKIN MICROBIOME 
 
Human skin is a multifaceted ecosystem (Dréno et al. 2017, Wilson et al. 
2005). The term microbiome is used to describe the collective genomes of the 
microorganisms that are resident on human skin (i.e. all of the microbes’ 
genes). Seen as an ecological community it is called microbiota. This complex 
ecosystem houses wide-ranging habitats on its nearly two square meter 
surface, reaching from humid environments in the axillary folds to dry areas 
of the shins and the back (Kong et al. 2017). Seen from the microbiome 
perspective, areas on human skin are usually divided into three environments, 
which all have their unique ecosystem and characteristic bacterial community 
(Figure 1, page 14, modified after Fyhrqvist et al. 2016): dry environment (e.g. 
on the back and the shins), moist environment (e.g. in the axillary and inguinal 
folds) and sebaceous environment (e.g. on the face and the scalp) (Prescott et 
al. 2017). The composition of the microbiome in each location is believed to be 
primarily defined by physical properties, but modulated by extrinsic and 
intrinsic factors (Grice et al. 2009).  
As a boundary to the outside environment, the skin is colonized by many 
micro-organisms, i.e. bacteria, fungi, mites and viruses (Grice et al. 2011). 
Most of these are now considered harmless and are even able to provide 
protection. For compensation the commensal bacterial community receives a 
body site or a biological niche to colonize in a symbiosis-based relationship 
(Zeeuwen et al. 2013, Grice et al. 2009). The cohabitation of microbes and 
host is multifaceted and should not be regarded as unilateral or stationary 
(Brandwein et al. 2016). Microbes have been reported to modify the host’s 
innate and adaptive immune system and play an important and dynamic role 
in the skin’s immune defense and barrier function (Campbell et al. 2017, 
Belkaid et al. 2016, 2014). Permanent interactions with the colonizing 
microbes teach cutaneous T-cells to recognize appropriate antigens and form 
immune responses correctly and they can be regarded as a part of the 
immunologic barrier of the skin (Naik et al. 2012). 
New molecular research methods have changed our view of the cutaneous 
microbial community (Kong et al. 2017). PCR-based methods have enabled us 
to understand the complex architecture and the dynamics of the human skin’s 
microbiome. Due to specific microbiome changes observed recently in 
inflammatory skin disorders, an interest has risen in developing new 
diagnostic methods and treatments (Eck et al. 2017).  
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2 REVIEW OF THE LITERATURE 
2.1 FACTORS THAT INFLUENCE THE MICROBIOME 
 
The microbiome of a specific body site is mainly defined by its physical 
characteristics: skin thickness, the number of skin folds and the amount of hair 
follicles, sweat and sebaceous glands (Szabó et al. 2017, Costello et al. 2009, 
Dréno et al. 2016). Individual features, e.g. age, gender and the immune 
system, also influence the microbial community (Baviera et al. 2014). Based 
on these endogenous and exogenous factors the resident bacterial community 
shows a wide variability in different regions and body sites of human skin 
(Figure 1, page 14) (Grice et al. 2009, Oh et al. 2014). Skin microbiome 
differences have also been explained by physiological and anatomical gender 
factors, such as sweat and sebum quality and amount, as well as hormonal 
differences. In studies conducted on healthy patient cohorts it has been shown 
that profession, environmental factors, e.g. use of antibiotics and skin care 
products modify the skin microbiome (Fierer et al. 2008, Ursell et al. 2012). 
Additionally, studies based on residence and cultural aspects have identified 
that a warm and humid climate is associated with increased microbial diversity 
of the skin (Costello et al. 2009). Once formed, the skin microbiome shows a 
remarkable stability in the same individual and can remain unchanged even 
despite various external factors, such as irritation, humidity and UV-radiation 
(Patra et al. 2016). Recent research indicates that the skin microbiome has an 
important role in maintaining a functional skin barrier (Baldwin et al. 2017). 
Skin colonization takes place instantly after birth (Costello et al. 2009, 
Costello et al. 2013). A new and interesting research field is the development 
and subsequent formation of the cutaneous microbiome during early life and 
its possible associations with skin disorders (Capone et al. 2011, Zeeuwen et 
al. 2013). Here, many exogenous and endogenous factors influence the 
formation of the skin microbiome (Costello et al. 2013). Intravenous 
antibiotics are known to have a negative impact on the bacterial diversity, 
whereas links of feeding habits and skin-to-skin contact or mode of delivery 
have showed inconsistent results in microbiome studies (Cooijmans et al. 
2017). It has been reported that for example gestational age has an effect on 
the cutaneous structure and function and is thus associated with the 
development of the skin microbiome in preterm infants (Pammi et al. 2017).  
In intensive care of preterm infants exogenous factors, such as medical 
devices (e.g. central venous line) and colonization from hospital employees or 
members of the family, have been reported to impact the skin microbiome 
(Groer et al. 2015). The microbial selection caused by antibiotic treatment, is 
a frequent problem in neonatal intensive care and seems to play a role also in 
the skin microbiome (Hartz et al. 2015). Especially the colonization of the 
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neonatal skin with Staphylococcus epidermidis and other coagulase negative 
commensal bacteria seem to play a role here (Bradford et al. 2011). There have 
been reports of a special susceptibility to coagulase negative commensal 
bacterial colonization due to skin and immunological immaturity (Costello et 
al. 2013). New molecular methods have enriched our understanding of the 
evolution and maturation of the healthy skin microbiome (Underwood et al. 
2017). It is possible that in the nearer future the modulation of pathogen 
colonization, e.g. staphylococci, in preterm and low birth weight infants can 
be done (Scharschmidt et al. 2017). 
 
2.2 INTERACTIONS OF THE MICROBIOME AND 
IMMUNE SYSTEM 
 
Besides the physical properties the skin is also as an immunological barrier 
(Belkaid et al. 2016). Maintenance and changes of the cutaneous microbiome 
are thus influenced by immunological factors (Campbell et al. 2017, Chen et 
al. 2013). In particular, the innate immune system has been shown to play an 
important role in the epidermal function (Pasparakis et al. 2014). There have 
been observations of a constant and dynamic interaction with commensal and 
Figure 1 The cutaneous microbiome in different body sites and environments, mean 
relative abundances of the most common genera (figure modified from data 
presented in Fyhrqvist et al. 2016) 
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pathogenic microbes (Skabytska et al. 2015, Dziarski et al. 2012, Dréno et al. 
2016).  
The innate immune system should consequently be viewed as a key element 
of the immunologic cutaneous barrier (Baldwin et al. 2017, Boguniewicz et al. 
2011, Gallo et al. 2011). Malfunctions have been shown to lead to insufficient 
responses to pathogens or persistent inflammatory states (Kuo et al. 2013, Lai 
et al. 2009). In recent studies it was demonstrated that also cells of the 
adaptive immune system (e.g. T-lymphocytes in the epidermis) are involved 
in supporting the function of the skin barrier (Belkaid et al. 2016, Brestoff et 
al. 2013). T-lymphocytes seem to be important in keeping up a tolerance to the 
commensal flora and in initiating immune responses against pathogens 
(Belkaid et al. 2014, Scharschmidt et al. 2017). 
2.3 NEW MOLECULAR RESEARCH METHODS 
 
Novel molecular research methods have had a strong impact on the 
understanding of the microbiome (Hugerth et al. 2017, Schaffer et al. 2017, 
Kong et al. 2017). Recent genomic studies on 16S ribosomal RNA (rRNA) gene 
sequencing (Kong et al. 2017, Dekio et al. 2007) have shown that the 
colonization of the skin is characterized by a great diversity and variability 
(Kong et al. 2011).  
These new molecular methods offer the possibility to investigate microbial 
communities without culture mediums and have thus broad application areas 
(Dréno et al. 2016). It is also relatively easy and noninvasive to obtain the 
cutaneous specimens (Prescott et al. 2017). Negative aspects of the PCR-based 
research methods are the absence of bacterial resistance testing possibilities 
and that the methods detect also dead micro-organisms (Brandwein et al. 
2016). With PCR-based microbiome research methods the current 
microbiome can be determined in a given point of time, but the dynamic 
content of bacterial genomes, including virulence factors and resistance 
mechanisms remain largely obscure (Findley et al. 2014). Due to their high 
sensitivity a frequent problem is furthermore contamination during sampling 
and laboratory analysis (Salter et al. 2014). A possible source of contamination 
are the person taking samples and the environment where the samples are 
obtained. It has also been shown that DNA extraction kits can be an important 
source of contamination. Other potential sources are the reagents used in the 
work-flow and the laboratory personnel handling the samples (Kong et al. 
2017, Salter et al. 2014). 
The standard sequencing process in investigating cutaneous specimens 
consist of swabs, scrapings or skin biopsies (Maguire et al. 2017, Kong et al. 
2011). The results of most of the published studies on skin microbiome are 
based on skin swabbing techniques (Egert et al. 2017). But it is acknowledged 
that the sampling technique may have an impact on the observed microbiome 
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data (Meisel et al. 2016, Grice 2015). Recently, in addition to the surface 
microbiome research, the investigation of deeper skin structures (i.e. the 
compartment-specific microbiome) has gained interest (Kong et al. 2017). 
Based on skin biopsy material some newer studies have also investigated the 
cutaneous microbiome in deeper cutaneous structures, such as the hair 
follicles and dermis (Ring et al. 2017).  
When investigating the cutaneous bacterial community the bacterial DNA 
is isolated and the 16S rRNA gene is amplified using PCR. It is recognized that 
some regions of the prokaryotic 16S rRNA gene, primarily the regions V1-V3, 
are the most suitable for investigating the skin microbiome (Egert et al. 2017). 
It has been noted, that especially the 16S hypervariable regions V1-V3 are best 
at discriminating bacterial taxa and identifying the bacteria at the genus level 
(Egert et al. 2017). Finally the amplified genes are sequenced on commercial 
platforms, e.g. MiSeq sequencer (Kozich et al. 2013). The immense 
microbiome data is analyzed using bioinformatic computer programs and 
tools such as mothur (Schloss et al. 2009). The final result of this approach is 
obtained by clustering and constructed based on the amount of sequence 
similarity (> 97 %) and named operational taxonomic unit (OTU) (Meng et al. 
2017). Based on this information it is possible to identify and classify most 
cutaneous bacteria to genus level, some even down to species level (Kong et al. 
2017).   
On the basis of rRNA gene polymorphisms the bacteria normally colonizing 
human skin can be divided into four phyla: Actinobacteria, Firmicutes, 
Proteobacteria and Bacteroidetes (Schommer et al. 2013). The proportions of 
these phyla seem to vary in different regions (Oh et al. 2014), but once the 
microbiome is formed and stabilized, it remains remarkably constant (Kong 
et al. 2011, Oh et al. 2016). Skin microbiome studies based on PCR-sequencing 
can provide us information about the occurrence of bacteria, the abundance 
and diversity of the bacterial community and whether specific bacteria are 
associated with a specific disease state or phenotype of skin disorder. They 
provide us information of the bacterial community at single time points, 
however they cannot prove a causal relationships between the skin 
microbiome and investigated disease (Grice et al. 2009). 
2.4 ASSOCIATION OF THE MICROBIOME AND 
INFLAMMATORY SKIN DISORDERS  
 
Inflammatory skin disorders, such as atopic dermatitis, have been shown to 
cause specific microbiome changes (Salava et al. 2014, Kong et al. 2012). It is 
still uncertain if these changes are caused by the microbiome itself or if they 
represent an epiphenomenon. Some studies have demonstrated a possible 
association to skin barrier malfunctions and immunologic dysfunctions 
(Belkaid et al. 2016, Seite et al. 2015, Zeeuwen et al. 2013).  
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Most extensive microbiome investigations have been conducted in patients 
with atopic dermatitis (Biedermann et al. 2015, Marrs et al. 2016, Fyhrqvist 
et al. 2016). In some studies the effect of commensal and pathogenic microbes 
has been suggested as an aggravating factor (Kong et al. 2012). Clinical 
improvement has also been demonstrated with treatments affecting the 
cutaneous microbiome (e.g. antimicrobial treatments) (Bjerre et al. 2017, 
Kong et al. 2012). During disease flares of atopic dermatitis a decrease in 
cutaneous microbial diversity has been observed (Harkins et al. 2017). A 
recovery to high bacterial diversity was shown after effective topical 
treatments (Figures 2 and 3, page 18, modified after Salava et al. 2014) (Seite 
et al. 2015).  
In a recent study (Harkins et al. 2017) on pediatric atopic dermatitis nasal 
and skin colonization by clonal Staphylococcus aureus populations 
(containing a single sequence type) was observed in both atopic dermatitis and 
controls. In the same study the later phylogenetic analyses showed that the 
disease flares that occurred over months, were associated with the clonal 
expansion of the S. aureus population (Harkins et al. 2017). It has also been 
shown that S. aureus colonization is increased in atopic dermatitis patients 
with filaggrin mutations (and other mutations of genes important for the 
epidermal barrier) (Clausen et al. 2017). Based on the results of this newer 
study the authors suggest that host-microbe interactions and differences in the 
S. aureus clones play an important role in the skin colonization of atopic 
dermatitis. There have also been reports of skin microbiome changes in 
psoriatic disease (Yan et al. 2017). In a recent study the authors detected an 
increased relative abundance of streptococci in the skin of psoriasis patients 
(Yan et al. 2017). 
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Figure 2 Relative abundances of the most common genera of the microbiome, patient 
with atopic dermatitis, stable disease state, moist environment (armpit), (figure
modified from data presented in Salava et al. 2014) 
Figure 3 Relative abundances of the most common genera of the microbiome, patient 
with atopic dermatitis, during disease flare, moist environment (armpit), (figure 
modified from data presented in Salava et al. 2014) 
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The role of S. aureus in inflammatory skin disorders has been under 
widespread investigation in the preceding years (Iwase et al. 2010, Lai et al. 
2009, Otto et al. 1999). There has been some evidence that during disease 
flares of atopic dermatitis the microbiome changes into more susceptible 
towards S. aureus colonization (Kong et al. 2012, Oh et al. 2013). There have 
also been reports that the commensal bacterial community inhibits the 
colonization of pathogens, especially S. aureus (Coates et al. 2014, Kong et al. 
2012).  
Interactions between the microbiome and the immune system seem to play 
a role in many skin disorders (Miodovnki et al. 2017, Zeeuwen et al. 2013). 
However, we have still only a limited understanding about their impact on the 
clinical picture and disease pathogenesis (Cerf-Bensussan et al. 2012, 
Atarashi et al. 2011). Many questions have remained unclear about the 
cutaneous microbiome, the host-microbiome relationship and its significance 
(Lee et al. 2017). 
2.5 CUTANEOUS MELANOMA 
 
Cutaneous melanoma is a malignant tumor arising from skin melanocytes 
(Tsao et al. 2017, Reginster et al. 2012). Its incidence and the need for 
therapeutic resources are expected to rise in the near future (Apalla et al. 2017, 
Tuong et al. 2012). Despite profound research the exact cause of melanoma 
has remained uncertain, but great progress has been made in recent years in 
terms of understanding the evolution and molecular pathogenesis of the 
tumor (Rajkumar et al. 2016).  
It has been shown that genetic and environmental causes play important 
roles in the initiation and progression of this malignant tumor (Hawkes et al. 
2016). Recognized environmental risk factors are UV-exposure and 
cumulative amount of sunburns (Kanavy et al. 2011). Mutations in proteins 
that regulate the cell-cycle are known to have an important role in the 
development of the malignancy (Tsao et al. 2017, Nikolau et al. 2012). 
Interactions between melanoma cells and host immune system have been 
investigated intensely (Tsao et al. 2017, Tietze et al. 2011). There have been 
reports of immune mediated regression of melanoma tissue (Byrne et al. 
2017). The individual immune response and immunologic characteristics are 
recognized to be important factors determining the initiation and progression 
of the disease (Mignogna et al. 2017). Some in vivo studies have reported of 
endogenous anti-melanoma immunity (Byrne et al. 2017, Pandolfi et al. 2011). 
Novel therapies that target the immune system, cell-cycle regulation and 
pathways have been developed and are used in disseminated disease (Amann 
et al. 2017, Chapman et al. 2011). However in localized disease surgical 
excision still remains the first line therapy (Garbe et al. 2016). Recognized 
important factors in patient management are an early detection and surgical 
 20 
removal of melanoma, which lead to a high cure rate and relatively good 
prognosis (Garbe et al. 2016, Bichakijan et al. 2011). In cases with metastatic 
disease response rates are still unfavorable and all current therapy regimens 
are not curative (Garbe et al. 2016). 
2.6 MELANOCYTIC NEVI 
 
Melanocytic nevi are very common and are based on localized proliferations 
of melanocytes (Huang et al. 2017). Histopathologically they can also have 
dysplastic features and then consequently are called dysplastic melanocytic 
nevi (Piccolo et al. 2016, Barnhill et al. 2010, Friedman et al. 2009). 
Regardless of the profound research in melanocytic nevi, our understanding 
about the etiology and pathogenesis have remained incomplete (Barnhill et al. 
2010). There are still distinct controversies about dysplastic nevi and their 
place as an entity in the range of melanocytic skin lesions (Rosendahl et al. 
2015). 
Genetics, sexual hormones and exposure to UV-radiation have been 
recognized as the most relevant etiologic factors in the development of 
melanocytic nevi (Huang et al. 2017, Lens et al. 2008). Similar mutations 
found in melanoma tissue (proteins that regulate the cell-cycle, e.g. BRAF 
V600E), have been detected in eruptive melanocytic nevi and dysplastic 
melanocytic nevi (Turner et al. 2005, Sekulic et al. 2010, Hawkes et al. 2016).  
There have been observations that immunological factors, such as 
immunosuppression, may play a role in both the development and growth of 
melanocytic nevi (Kim et al. 2016, Zattra et al. 2009). In patients with 
immunosuppression, e.g. patients receiving chemotherapy, a greater 
incidence of melanocytic nevi and dysplastic nevi has been described (Kim et 
al. 2016, Chen et al. 2014). There have also been reports of eruptive 
melanocytic nevi in association of immunosuppressive therapy in children 
(Vena et al. 2017, Reutter et al. 2007). 
2.7 THE MICROBIOME AND CANCER  
 
The possible association between the microbiome and malignancies is a recent 
hypothesis and has to our knowledge not been formerly investigated in skin 
cancer (Yu et al. 2015). The microbiome is present predominantly in 
epidermal and mucosal locations: skin, mucosal surfaces, lung and the 
intestine. It is now known that the microbiome interacts profoundly with its 
host and especially with the epithelial surface (Chen et al. 2017). A dysbiosis 
of the microbiome is believed to play a role in some human cancers, but strong 
evidence for this is still missing (Chen et al. 2017). Most microbiome studies 
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have been conducted in gastrointestinal and oral cancer (Mima et al. 2017, 
Schmidt et al. 2014), where results have been inconsistent and conflicting and 
the role of the gastrointestinal microbiome in the pathogenesis of intestinal 
malignancies has remained unclear (Singh et al. 2017, Yu et al. 2015).  
It is known that specific bacterial pathogens such as Helicobacter pylori 
may initiate gastrointestinal carcinogenesis (Noto et al. 2017). On the other 
hand, in a recent study (Ferreira et al. 2017) the microbiome in gastric 
carcinoma was found to have a reduced microbial diversity and decreased 
abundance of Helicobacter. The authors also found an enrichment of 
intestinal commensal bacteria and calculated a dysbiosis index, which is 
believed to discriminate between chronic inflammation (gastritis) and 
malignant proliferation (gastric carcinoma). Reports of commensal bacteria-
induced chronic inflammation and progression of malignancies of other organ 
systems have also been published (Oke et al. 2017, Arthur et al. 2012, 
Maslowski et al. 2009, Mima et al. 2017). In another recent study on lung 
cancer the authors found a significant decrease in the bacterial diversity of the 
lower airway (bronchial brushing sample) on the side of lung cancer, when 
compared to the same patients’ healthy contralateral bronchi (Liu et al. 2017). 
The authors used the contralateral lower airway microbiome as control and 
discussed that investigating the microbiome could possibly be used as a lung 
cancer screening method in the future. Other authors have discussed 
microbiome studies as a possible target for prevention and treatment of 
chronic inflammatory airway diseases, such as asthma (Chung 2017). 
In inflammatory bowel diseases bacterial components such as 
lipopolysaccharides have been demonstrated to maintain gastrointestinal 
inflammation and the disease progression (Baillie et al. 2017). In a recent 
study on colitis ulcerosa associated colon cancer the intestinal microbiome was 
reported to be significantly different from sporadic colon cancer and healthy 
individuals (Richard et al. 2017). The authors also did a comparison of the 
tumour site and normal mucosa near the tumour site, but the microbiome did 
not differ significantly and showed a similar pattern. In gastrointestinal cancer 
the global mucosa-associated bacterial microbiome has been characterized as 
decreased in microbial biodiversity (Kang et al. 2017). It has been postulated 
that a chronic inflammatory state initiates carcinogenesis by Toll-like receptor 
signalling (Bhatt et al. 2017, Mazmanian et al. 2008), however it is still mainly 
unclear how changes in the microbiome and the host inflammatory response 
lead to malignancy, e.g. colorectal cancer (Louis et al. 2014). 
Recently there have been reports of a possible role of the vaginal 
microbiome in gynaecologic malignancies. The results have been controversial 
(Champer et al. 2017). Additionally, studies about the role of the microbiome 
in malignancies of other organ systems, e.g. lung cancer, have been now 
initiated (Cameron et al. 2017, Rajagopala et al. 2017). The role of the 
cutaneous and lactic gland microbiome in the pathogenesis of breast cancer 
has been discussed (Mani 2017). Microbiome studies have raised an interest 
in finding potential biomarkers (primarily characteristics in the microbiome 
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data) for cancer diseases, e.g. lung cancer. In a recent microbiome study on 
lung cancer the authors concluded that spontaneous sputum appears to have 
potential for bacterial microbiome-based biomarkers, which may be utilized 
also clinically (Cameron et al. 2017).  
Microbiome studies have evolved as interesting novel perspectives in 
cancer research. However, many questions about the role of the microbiome 
in initiation and progression of malignancies still remain unclear. Altogether, 
these novel microbiome studies have contributed to our understanding of how 
the normally symbiotic and commensal bacterial community can effect 
processes like chronic inflammation and cancer development and progression. 
Additionally, we have gained more insights into the role of the microbiome in 
modulating the environmental effects on the host and carcinogenesis. The 
interest has been particularly in exogenous factors (e.g. diet, antibiotics) which 
directly affect the commensal bacterial communities (Dmitrieva et al. 2017). 
In case of the skin microbiome the most important factors appear to be the 
exposition to UV-radiation, but this has not been studied systematically (Patra 
et al. 2016, Chen et al. 2017). There is a complex relationship between, on one 
side the commensal and pathogenic microbes and the other side, host 
immunity and metabolism (Fulbright et al. 2017). In cancer research 
microbiome studies have revealed unexpected and exciting results, which have 
to be confirmed in larger patient groups. It will be interesting to see, if the 
investigation of the microbiome will influence future therapies and possible 
prevention of malignant diseases. 
2.8 THE MICROBIOME AND LYMPHOPROLIFERATIVE 
DISEASE 
 
Parapsoriasis belongs to the spectrum of cutaneous lymphoproliferative 
disorders (Cerroni 2017). On one side there is a picture resembling chronic 
dermatitis and on the other a picture similar to cutaneous T-cell lymphoma 
(Burg et al. 2002). At present it is still unknown what initiates parapsoriasis 
and what are the factors that lead to progression of the disease. The 
development and disease course cannot be efficiently predicted (Lewin et al. 
2012). To our knowledge microbiome studies have not been conducted before 
in lymphoproliferative diseases or in parapsoriasis. 
Traditional classifications classify parapsoriasis into small plaque (SPP) 
and large plaque parapsoriasis (LPP). Both subtypes may follow a chronic 
course for many years. Molecular studies have shown that parapsoriasis is a 
monoclonal cutaneous T-cell disorder (Sibbald et al. 2016). T-cell receptor 
gene rearrangement and sensitive polymerase chain reaction (PCR)-based 
tests have demonstrated, that the pathogenic T-cells in parapsoriasis belong 
to the skin-associated lymphoid tissue (SALT) (Leloup et al. 2014).  
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T-cell infiltration in parapsoriasis can be divided into two main patterns:  
 
1. Superficial eczema-like type of inflammation (with a sparse infiltration 
of mature lymphocytes around the superficial capillaries and only some 
lymphocytes invading into the epidermis) 
2. Atypic lymphocyte infiltration-type (with a band-like lymphocytic 
infiltration with some lymphocytes infiltrating diffusely into the 
epidermis) (Baderca et al. 2014, Leloup et al. 2014, Väkevä et al. 
2005). 
 
The typical histologic picture of parapsoriasis in comparison with normal skin 
is demonstrated in figure 4, page 23 and figure 5, page 24. There is current 
consensus that both clinical subtypes can progress into cutaneous T-cell 
lymphoma, mainly mycosis fungoides (Berg et al. 2017, Lindahl et al. 2014). 
The risk for malignant transformation is known to be higher in large plaque 
parapsoriasis (Cerroni 2017). 
 
Figure 4 Histopathology of normal skin, HE-staining, 20-fold magnification, there is no 
notable T-cell infiltration in the dermis, figure by Katriina Lappalainen M.D., 
Ph.D., with permission 
 24 
 
2.9 PROGRESSION INTO CUTANEOUS T-CELL 
LYMPHOMA 
 
It has been observed that approximately 30 % of the cases of large plaque 
parapsoriasis progress into cutaneous T-cell lymphoma, mostly mycosis 
fungoides (Talpur et al. 2017, Väkevä et al. 2005).  
Based on the clinical picture or on histopathology it can be impossible to 
differentiate LPP from early cutaneous T-cell lymphoma (for example mycosis 
fungoides) (Kikuchi et al. 2003, Eklund et al. 2016). No marker has been found 
to recognize the cases that are susceptible to lymphoma transformation 
(Leloup et al. 2013). Prognostic factors that would indicate a possible 
progression into cutaneous T-cell lymphoma are currently not available. There 
are also no tests existing to differentiate between benign and malignant 
cutaneous T-cell infiltration and if the disease is going to develop into 
malignancy (Sibbald et al. 2016). 
Figure 5 Histopathology of parapsoriasis, HE-staining, 20-fold magnification, T-cell 
infiltration takes mainly part in the dermis, the epidermis contains only single 
atypical T-lymphocytes (arrow), figure by Katriina Lappalainen M.D., Ph.D., 
with permission 
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In large plaque parapsoriasis the quantity of malignant monoclonal cells in 
the skin has been reported 1 % to 10 %, while in mycosis fungoides it can extent 
to 50 % (Howard et al. 2000). Although some cases progress to lymphoma, 
parapsoriasis in the most cases has a benign course and stays indolent for 
many years. There have been cases with complete resolution. Various 
prognostic parameters such as histopathology, immunohistochemistry, PCR 
and T-cell receptor gene rearrangement studies have been investigated. The 
main goal has been to characterize the atypical lymphocytes, and thus to 
predict the disease course (Scarisbrick 2017, Costa et al. 2003, Väkevä et al. 
2005). 
Parapsoriasis patients require a dermatological follow up and often 
repeated skin biopsies to exclude cutaneous T-cell lymphoma. Small or large 
plaque parapsoriasis can be treated symptomatically with topical 
corticosteroids or phototherapy, e.g. psoralen plus UVA-therapy (Duarte et al. 
2013). Systemic therapies can be considered in severe cases and when there 
are signs of progression into cutaneous T-cell lymphoma (Trautinger et al. 
2017). 
2.10 CUTANEOUS T-CELL LYMPHOMA AND 
STAPHYLOCOCCAL ENTEROTOXINS 
 
Several recent studies have demonstrated an intense interaction between the 
cutaneous microbiome and the host’s immune system (Belkaid et al. 2016, 
Kikuchi et al. 2003, Cerf-Bensussan et al. 2012). In addition to the skin’s 
physical functions, the innate immune system and the commensal bacteria 
have shown to play a role in the cutaneous immunological barrier (Wanke et 
al. 2011, Burg et al. 2002).  
There have been reports that staphylococcal enterotoxins (e.g. enterotoxin 
A, SEA) from affected skin of cutaneous T-cell lymphoma induces in vitro IL-
17 production in primary malignant T cells of lymphoma patients (Litvinov et 
al. 2016). Here, malignant T-cells produced interleukins when they were 
cultured with autologous nonmalignant T-cells. This observation was not 
made in monocultures of malignant T-lymphocytes (Willerslev-Olsen et al. 
2016). 
2.11 THE SKIN MICROBIOME IN PRETERM INFANTS 
 
It has been shown that the cutaneous microbiome in preterm neonates and 
infants undergoes significant changes in early life (Costello et al. 2013, Capone 
et al. 2011). Observations of microbiome studies suggest that before the skin 
microbiome is established during infancy and consequently turns into a 
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relatively stable state, it is initially characterized by substantial dynamics and 
variations (Pammi et al. 2017). The main reasons for this development have 
remained obscure. A study with healthy neonates found that neonates were 
colonized with cutaneous bacterial communities that were undifferentiated 
across many body sites, regardless of the birth delivery mode (Dominguez-
Bello et al. 2010). This was observed in direct contrast to the complex and 
differentiated bacterial communities of their mothers. Although the skin 
microbiome of healthy neonates is characterized quite well, we have only a 
limited amount of knowledge of it in preterm and very low birth weight infants 
(birth weight < 1500 g) (Costello et al. 2013, Pammi et al. 2017). To our 
knowledge microbiome studies in very low birth weight infants in intensive 
care have not been carried out before. 
The variety of microorganisms that colonize the new-born skin differs 
depending on many intrinsic and extrinsic factors (Underwood et al. 2017). 
The skin microbiome has been shown to change when physiological functions, 
e.g. the barrier function of the skin, are disturbed (Costello et al. 2013). S. 
epidermidis is a typical bacterium of the commensal bacterial community of 
human skin. Apart from its commensal role, recent studies (Byrd et al. 2017, 
Soerg et al. 2017) have suggested that it could also be an important factor to 
the general health of neonates (Pammi et al. 2017). S. epidermidis has a role 
in the inhibition of virulent pathogens and interactions with the immune 
system (Bradford et al. 2011, Becker et al. 2014). In a recent study it was 
observed that skin colonization by commensal bacteria (including S. 
epidermidis) and local chemokine production together recruit regulatory T-
cells into neonatal skin (Scharschmidt et al. 2017). The authors suggested that 
because regulatory T-cells are important for immune tolerance, early life 
interactions with commensal microbes seem to play an important role in 
establishing this tolerance. The results of another study on the microbiome of 
preterm neonates showed that the characteristics of the neonatal skin 
microbiome did not differ between different body sites for in term and preterm 
infants during the neonatal period (Pammi et al. 2017). It was however shown, 
that the cutaneous microbial diversity was positively associated with the 
gestational age during early life. As observed in a former study (Costello et al. 
2013), the authors concluded that in preterm neonates intravenous antibiotics 
are likely to have a negative impact on the skin’s bacterial diversity. Contrary 
to the results of a previous study on healthy neonates (Dominguez-Bello et al. 
2010), the authors did not see differences with respect to feeding (e.g. breast 
feeding or milk substitutes) or mode of delivery. 
The skin colonization with commensal bacteria, such as S. epidermidis and 
other coagulase negative bacteria, takes place shortly after birth (Rogers et al. 
2016, Costello et al. 2013). During intensive care treatment, many factors seem 
to have an effect on the cutaneous bacterial community (Pammi et al. 2017). 
There have been reports that invasive procedures and devices, colonization 
from health care workers or family members and the microbial selection 
caused by antibiotic treatment, alter the microbiome (Chu et al. 2017, Power 
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Coombs et al. 2013). Our understanding of the skin microbiome and its 
dynamics in early life of neonates and especially that of preterm and very low 
birth weight neonates is still incomplete. Above all the impact of skin 
microbiome changes on health and development of infants and the possible 
association with skin disorders remains to be elucidated. 
2.12 NEONATAL SEPSIS AND STAPHYLOCOCCI 
 
Neonatal sepsis is a frequent clinical problem in intensive care of premature 
and low to very low birth weight neonates (Shane et al. 2017, Bekhof et al. 
2013). Sepsis diagnosis can be challenging because the presenting symptoms 
are frequently unspecific (Larson et al. 2005, Tsai et al. 2014). Microbiome 
studies investigating the possible link between neonatal sepsis and the 
gastrointestinal microbiome have been carried out, but results have been 
controversial (Berrington et al. 2014). In a twin study it was shown that 
preterm twins share a similar gut microbiome, which is modulated by the 
complex environment of the intensive care unit (Stewart et al. 2013). The 
authors concluded that it was likely a result of genetic and immunologic factors 
as well as exposure to the same maternal microbiome during birth, skin-to-
skin contact and breast milk. No association to neonatal sepsis was detected 
(Stewart et al. 2013) and the authors suggested that skin colonization and 
invasive medical devices would more likely to be linked to neonatal sepsis. 
Until now, microbiome studies that investigate the possible association 
between the cutaneous microbiome of preterm neonates and neonatal sepsis 
have to our knowledge not been carried out. It seems however, that 
environmental factors including prematurity of the skin barrier, invasive 
medical procedures and antibiotic exposure play a role in colonization of the 
neonates’ skin by staphylococci (Chu et al. 2017). Other factors that have been 
discussed are the structure of the microbial community and host genetics 
(Mutic et al. 2017, Pammi et al. 2017). The premature skin of neonates is 
known to be susceptible to colonization by coagulase negative commensal 
bacteria (Groer et al. 2015). The main reasons for this are believed to be 
immaturity in the skin barrier function and the immune system (Underwood 
et al. 2017, Capone et al. 2011).  
It has been demonstrated that coagulase-negative staphylococci, in 
particular S. epidermidis, are the main pathogens in neonatal sepsis (Dong et 
al. 2014). Over 80 % of the sepsis cases in preterm low birth weight neonates 
are caused by S. epidermidis (Garite et al. 2017, Rupp et al. 2014). Intensive 
treatment and the use of invasive medical treatments, e.g. with a central 
venous line, are believed to increase the risk for neonatal sepsis (Garite et al. 
2017). Different factors of intensive care seem also to have an additive role in 
influencing the skin microbiome: invasive medical devices, colonization from 
hospital employees and members of the family, as well as microbial selection 
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by antibiotics (Alcock et al. 2017). Subsequently, in most preterm neonates the 
skin is initially colonized with S. epidermidis and other coagulase negative 
commensal bacteria (Dong et al. 2014, Li et al. 2013). 
2.13 THE SKIN MICROBIOME AND NEONATAL SEPSIS 
 
Previous microbiome studies have shown, that based on the immature 
cutaneous barrier and undeveloped immune system neonates have a 
predisposition to cutaneous bacterial diversity changes (mainly decreased 
diversity) and to skin colonization by coagulase negative commensal bacteria 
(Nakamizo et al. 2015, Bokulich et al. 2016).  
The microbiome of preterm neonates seems to undergo profound changes 
in early life (Pammi et al. 2017). It seems to be dominated by coagulase-
negative staphylococci, mainly S. epidermidis (Capone et al. 2011). Because 
these bacteria are also the accepted pathogens of neonatal sepsis, there has 
been an interest in investigating the skin microbiome in preterm neonates (Li 
et al. 2013).  In general, intensive care is known to have a profound effect on 
the cutaneous microbiome of preterm neonates, but our knowledge about its 
relationship to neonatal sepsis remains unclear (Groer et al. 2015, Costello et 
al. 2013). Environmental factors of the intensive care unit, such as caregiving 
equipment (especially invasive medical device), colonization from medical 
personnel and antibiotic use seem to play a major role for the skin microbiome, 
but the causality to neonatal sepsis is still controversial (Hartz et al. 2015). 
Altogether, there have been only a limited amount of studies investigating 
the possible association between the observed skin microbiome changes and 
neonatal septic infections, particularly neonatal sepsis. Currently, our 
knowledge about the skin microbiome in preterm infants is still incomplete 
and there is only a small quantity of skin microbiome data in this patient 
group. In a recent review article it has been discussed (Rodriguez et al. 2017) 
that various factors in the neonatal intensive care ward influence the skin 
microbiome and that this information could also be used to establish clinical 
guidelines in neonatal intensive care. The authors point out that the 
prevalence of nosocomial infections can be decreased by concrete skin 
targeted measures: infection control (e.g. venous catheters), encouraging of 
skin-to-skin care and breast feeding and whenever possible decreasing the use 
of antibiotics (Rodriguez et al. 2017, Hartz et al. 2015, Groer et al. 2015). 
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3 OBJECTIVES OF THE PRESENT STUDY 
1. 
In study I the aim was to characterize the microbiome in cutaneous melanoma 
and in benign melanocytic nevi. The study was targeted to investigate whether 
there are any differences in diversity or specific bacterial taxa between the 
same patients’ healthy skin, melanomas and melanocytic nevi.  
 
2.  
In study II the aim was to characterize the skin microbiome in small and large 
plaque parapsoriasis. Parapsoriasis is known to precede mycosis fungoides, 
the most common form of cutaneous lymphoma. Study II was targeted to 
investigate whether the chronic parapsoriasis lesions would have a different 
skin surface microbiome compared to the individual’s healthy (nonlesional) 
skin sites. The goal was to explore if there is an association of any specific 
bacterial community (especially S. aureus) with the chronic T-cell 
proliferation of parapsoriasis. In addition, we wanted to investigate if 
microbiome swab sampling could be helpful as a diagnostic method in 
parapsoriasis. 
 
3.  
Based on previous studies and suggested links between neonatal sepsis, 
staphylococci and microbiome changes, our aim in study III was to 
characterize the cutaneous microbiome of very low birth weight infants during 
the first postnatal weeks in neonatal intensive care. The goal was also to 
explore the possible association of microbiome changes and neonatal sepsis. 
Because of limitations in the clinical setting (intensive care, sepsis treatment) 
it was only possible to conduct study III as a case study. 
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4 METHODS 
4.1 PATIENT STUDIES  
 
The ethics committee of the Helsinki-Uusimaa Hospital District, Helsinki, 
Finland, approved the study protocols (approval number studies I-II: 
12/13/03/01/2012, study III: 103/13/03/03/2012). 
4.1.1 STUDY I 
 
The clinical part was carried out between February 2012 and January 2014 at 
the Department of Dermatology and Allergology, Helsinki University 
Hospital, Finland. 
Microbiome swab samples of melanomas (Figure 6, page 32) and 
melanocytic nevi from 52 different patients were examined. Samples from 20 
patients had to be excluded from the microbiome analysis because of 
inappropriate lesion type (e.g. dysplastic nevus, blue nevus) or unsatisfactory 
amount of DNA. 
4.1.2 STUDY II 
 
The clinical part was carried out between January and September 2014 at the 
Department of Dermatology and Allergology, Helsinki University Hospital, 
Finland. 
Altogether 13 patients with histologically confirmed parapsoriasis (6 with 
small plaque parapsoriasis and 7 with large plaque parapsoriasis) were 
investigated. 
4.1.3 STUDY III 
 
The clinical part was carried out between March and October 2013 in the 
neonatal intensive care unit (NICU), Children’s Hospital, Helsinki University 
Hospital, Finland. 
Microbiome samples from 12 randomly selected preterm very low birth 
weight (VLBW) infants were taken on several days during intensive care. The 
patients were given mother-infant skin-to-skin care and prophylactic primary 
antibiotics after birth. Neonates with sepsis were given antibiotic treatment 
according to their symptoms and sepsis treatment guidelines. 
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4.2 SAMPLE COLLECTION 
4.2.1 STUDIES I AND II 
 
Skin microbiome samples were obtained with a sterile swab that was 
immersed into a buffered solution. The borders of the investigated skin lesions 
were not overlapped and the skin was not handled or disinfected before 
sampling (Figure 7, page 32) (Dréno et al. 2016). 
Control specimens were taken using the same method from the patients’ 
healthy skin on the contralateral body sites (Figure 8, page 33) (Ursell et al. 
2012). The microbiome samples were deposited directly in liquid nitrogen and 
conserved. Melanomas and nevi were subsequently removed surgically and 
parapsoriasis lesions were biopsied for histopathology. 
4.2.2 STUDY III 
 
The samples were taken in the intensive care ward by three educated nurses 
from the infants’ abdomen and the incubators. 
The same sampling protocol as in studies I and II was used. All samples 
were obtained from the same body sites at the same time of the day. The 
samples of the first day were taken after relocation of the infants from the 
delivery room and after the administration of primary antibiotics. 
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Figure 6 Superficially spreading melanoma, Breslow 0,85 mm, Clark IV, on the upper 
back of a patient, non-invasive microbiome swab samples were taken from the 
overlying skin (patient from study I), figure with permission of the patient 
Figure 7 Swab sampling from a melanocytic nevus (patient from study I), figure with 
permission of the patient 
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4.3 DNA EXTRACTION, PCR AMPLIFICATION AND 
SEQUENCING 
 
All molecular studies were conducted at the Institute of Biotechnology, 
University of Helsinki, Finland. Laboratory analysis followed the general rules 
and regulations of the University of Helsinki. 
The bacterial DNA was extracted from the conserved swab sticks by using 
the commercially available FastDNATM Spin Kit for Soil (MP Biomedicals) 
based on the manufacturer’s instructions. In all studies the PCR amplification 
was performed with the ARKTIK Thermal Cycler (Finnzymes Diagnostics, 
Thermo Scientific) in two stages (Grice et al. 2009). 
The PCR protocol was carried in the following steps: In the first step 25 μl 
of technical replicates of each sample were analyzed. The template DNA 
quantity ranged from 23 to 58 ng. Primers of the first step targeted the variable 
V1-V3 regions of the bacterial 16S rRNA gene. The primer sequences were the 
following: pA (AGAGTTTGATCMTGGCTCAG) (Lane et al. 1991) and pD’ 
(GTATTACCGCGGCTGCTG) (Edwards et al. 1989) and partial Illumina 
TruSeq adapter sequences (ATCTACACTCTTTCCCTACACGACGCTCTTCCGA 
TCT and GTGACTGGAGTTCAGACGTGTGCTCT TCCGATCT,  
correspondingly) added to the 5’ ends of the primers. 
Figure 8 Microbiome swab specimens were collected from lesional parapsoriasis skin 
(left flank) and contralateral healthy skin (right flank), both marked with black 
circles (patient from study II), figure with permission of the patient 
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The subsequent PCR program was carried out in the following way: Firstly, 
DNA denaturation at a temperature of 98 °C, followed by 15 cycles at 98 °C for 
10 s, 65 °C for 30 s, and 72 °C for 10 s, and finally an extension for 5 min at 72 
°C. During every PCR run a PCR blank without any template DNA was 
included in the analysis. Before moving to the second step, a purification of the 
PCR products was carried out with Exonuclease I (Thermo Scientific) and 
Thermosensitive Alkaline Phosphatase (FastAP; Thermo Scientific). A sample 
(5 μl) of the first PCR step was used also for the second PCR step. During the 
second step the PCR run was carried out with full-length TruSeq P5 and Index-
containing P7 adapters, and a PCR program identical to the first, except with 
18 cycles. Finally, the PCR products were purified with Agencourt AMPure XP 
magnetic beads (Beckman Coulter). In study I sequencing was carried out 
using the 454 GS FLX Titanium chemistry (Roche Diagnostics) and in studies 
II and III using the Illumina MiSeq platform in two separate sequencing runs. 
Additionally, two kit controls (extraction made without sample material) and 
three PCR blanks (PCR run without template DNA) were sequenced. The most 
important steps of the molecular study protocol are illustrated in figure 9, page 
34. 
 
DNA-extraction from frozen swab specimens 
(FastDNATM Spin Kit) 
 
 
 
PCR-amplification in two stages 
(ARKTIK Thermal Cycler) 
 
 
 
 
Purification of the final PCR products 
(Agencourt AMPure XP magnetic beads) 
 
 
 
 
Sequencing of the final DNA pool  
(Platforms: 454 GS FLX Titanium chemistry, study I, 
 Illumina MiSeq, studies II and III) 
 
Figure 9 Protocol of DNA-extraction, PCR-amplification and microbiome sequencing 
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4.4 BIOINFORMATIC AND STATISTICAL ANALYSIS 
 
In studies I-III the initial quality control and primer removals were carried 
out with cutadapt (Martin et al. 2011). Sequence data was analyzed using 
mothur following the Standard Operating Procedures for 454 data (study I) 
(Schloss et al. 2009) and MiSeq-sequenced 16S rRNA data (studies II and III) 
(Kozich et al. 2013). 
In study I the following tag and primer sequences and any sequence reads 
were interpreted to have low quality and removed: any mismatches to the 
barcode or > 2 mismatches to the forward primer, any ambiguous nucleotides, 
homopolymers > 8 nucleotides and sequence length of  < 200 nucleotides. In 
addition, the sequences were denoised using mothur’s application of the 
PyroNoise algorithm (Quince et al. 2009). An alignment of the sequences to 
the SILVA 123 database was carried out, and any sequences that did not align 
correctly were removed. Chimeric 16S rRNA sequences were removed using 
UCHIME (Edgar et al. 2011). Finally, based on mothur’s naïve Bayesian 
classifier (the RDP taxonomic outline as the training set against the SILVA 123 
database), the good quality sequences were assigned taxonomical 
classifications. The sequences were grouped at 97 % sequence identity to OTUs 
(Operational Taxonomic Units). Thus, after all quality control steps, such as 
trimming, denoising, alignment, and removal of chimeric sequences and non-
bacterial reads a sequence rarefication was carried out. Rarefaction is a 
technique to assess species richness from the results of sampling and allows 
the calculation microbial diversity based on the construction of rarefaction 
curves. 
In studies II-III cutadapt was used to trim primers and low-quality ends 
of sequences from the data, with the parameters -q 30 for both reads and -m 
200 for the forward, -m 180 for the reverse read. Pairing the reads, further 
sequence quality control and taxonomic classification were done with mothur 
(recommended procedure for MiSeq-sequenced 16S rRNA data) (Kozich et al. 
2013). All singleton OTUs were trimmed before further analysis. 
The statistical analysis and data visualization were performed in all studies 
with R (R version 3.2.3, R Core Team 2015). In studies I-II a NMDS ordination 
was made with phyloseq using the Bray-Curtis distance and rarefied 
microbiome data (McMurdie et al. 2013). All statistical comparisons were 
carried out in R using DESeq2 package (Love et al. 2014). Alpha diversity 
indices were calculated in Vegan (Oksanen et al. 2013) package using R with 
Kruskal-Wallis rank sum (kruskal.test) and Wilcoxon rank sum tests 
(pairwise.wilcox.test). 
In study II the staphylococcus sequences were further investigated using 
oligotyping (Eren et al. 2013). Oligotyping is new a method of improving the 
accuracy of DNA sequence analysis. It is a computer-based method that may 
reveal masked bacterial diversity within the final operational units of 
classification or clustering based DNA sequencing approaches. Oligotyping 
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data is obtained with biostatistical tools (mainly entropy analysis) of variable 
sites in the sequences (Eren et al. 2013). Compared with molecular databases 
or cluster analyses the investigated sequences in oligotyping primarily map to 
the same taxon (Ramette et al. 2014). Differently from former methods that 
compare all positions in sequence reads, oligotyping uses only selective 
sequence information of the 16S rRNA gene variable sites (Eren et al. 2015).  
In study III, to enable diversity comparisons, an inverse Simpson value > 
2 was determined as high diversity and ≤ 2 as low diversity. 
4.4.1 ACCESSION NUMBERS OF THE EUROPEAN NUCLEOTIDE 
ARCHIVE 
 
The sequencing data has been deposited to the European Nucleotide Archive: 
http://www.ebi.ac.uk/ena (Toribio et al. 2016, Human Microbiome 
Jumpstart Reference Strains Consortium 2010).  
 
Accession numbers: 
Study I: PRJEB7554, Study II: PRJEB15287, Study III: PRJEB12986 
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5 RESULTS 
5.1 STUDY I 
 
The microbiome data in study I was obtained from patients with cutaneous 
melanoma and the same patients’ healthy skin, and from patients with benign 
melanocytic nevi and the patients’ healthy skin. The data contained 2826 
OTUs representing 483 genera, 40 classes and 25 phyla. 99 % of the OTUs 
belonged to four phyla: Firmicutes (mainly the classes Clostridia and Bacilli), 
Actinobacteria (class Actinobacteria), Proteobacteria (mainly Alpha-, 
Gamma-, and Beta-) and Bacteroidetes (class Bacteroidia). On the genus level 
Propionibacterium (50.49 %) was the most common, followed by 
Staphylococcus (13.41 %) and Corynebacterium (9.55 %). 
The microbiome data of melanomas, melanocytic nevi and the 
corresponding control samples were similar to each other. There was a notable 
variation between individual patients. Statistically significant differences were 
observed in several bacterial taxa and in different body sites but none of these 
showed a consistent pattern. There were no significant differences in bacterial 
diversity between lesions and control samples (Wilcoxon rank sum test, p = 
0.99 for both pairs). Group comparisons (4 groups, Inverse Simpson indices) 
of melanomas, melanocytic nevi and controls showed no statistically 
significant differences (Kruskal-Wallis rank sum test, p = 0.3074). The 
comparison of all melanoma samples against all melanocytic nevi was near to 
statistical significance (2 groups, Kruskal-Wallis rank sum test, p = 0.0579). 
5.2 STUDY II 
 
The microbiome data was obtained from patients with parapsoriasis and their 
contralateral healthy skin. It represented a total of 410 genera, 39 classes and 
21 phyla. 89 % of the sequences represented four phyla: Actinobacteria (class 
Actinobacteria, 59.37 %), Firmicutes (mainly the classes Clostridia and Bacilli, 
15.02 %), Proteobacteria (mainly Alpha-, Gamma-, and Betaproteobacteria, 
12.46 %) and Bacteroidetes (mainly Bacteroidia, 2.16 %). At the phylum level 
10.19 % of the sequences remained unclassified. At the genus level the most 
common were Propionibacterium (27.13 %), Corynebacterium (21.20 %) and 
Staphylococcus (4.63 %). 
Staphylococcus species in the microbiome data were further investigated 
by oligotyping. This was carried out to more accurately investigate the 
staphylococcus sequences and to find out if the lesional skin microbiome in 
parapsoriasis contained S. aureus. Oligotyping is used as a novel method of 
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improving precision in DNA sequencing. The rationale behind it was, that 
oligotyping could possibly reveal staphylococcal bacterial sequences within 
the operational taxonomic units that would have been masked by the 
previously utilized traditional approaches. The sequences could be divided 
into five oligotypes. The most common were S. epidermidis (39.63 %), 
Staphylococcus hominis (33.34 %) and Staphylococcus capitis (21.50 %). The 
remaining two oligotypes (4.61 % and 0.92 %) could not be recognized, but the 
microbiome data did not contain S. aureus. 
No significant differences were observed between control and lesional 
parapsoriasis samples (Kruskal-Wallis rank sum test; p > 0.34 for both 
indices). There were also no significant differences between small and large 
plaque parapsoriasis (p > 0.57 for both indices). Comparable to the results of 
study I, the microbiome data of the same patient’s lesional and control skin 
were similar to each other. 
5.3 STUDY III 
 
The microbiome data was acquired from the abdominal skin of 13 preterm, 
very low birth weight infants. Here, the data showed a high cutaneous 
microbial diversity in nearly all infants at birth (with the exception of infant 
number 1). During intensive care treatment the diversity changed 
substantially in all of the infants. The relative abundances of bacteria in the 
microbiome data were comparable with previous findings of infant skin 
(Capone et al. 2011, Costello et al. 2013). The most common phyla at birth 
were Firmicutes, Actinobacteria, Proteobacteria and Bacteroidetes. At the 
genus level the most common were Propionibacterium, Staphylococcus and 
Corynebacterium. 
In both septic and non-septic infants a notable decrease in cutaneous 
bacterial diversity was observed within the first 3 weeks of intensive care. In 
septic infants this observation was made before antibiotic treatment for 
neonatal sepsis. 
After the decrease in diversity the cutaneous microbiome was dominated 
by high abundances of one OTU, which was similar to S. aureus. 
(Staphylococcus Otu00007). The exception was infant number 7, where this 
OTU was not observed. A recovery of higher cutaneous microbial diversity was 
seen in 6 of the 12 infants (50 %) during intensive care treatment and after the 
ending of antibiotic treatment. There were no temporal associations between 
decrease of microbial diversity and sepsis. In septic infants the recovery of high 
cutaneous diversity was not connected with clinical recovery from sepsis. All 
infants had received prophylactic antibiotics immediately after birth. The 
antibiotic treatment given to septic infants showed no effect on the cutaneous 
microbiome. Inflammatory parameters (e.g. C-reactive protein, blood 
leucocyte count) were higher in septic infants, but showed no consistent 
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association with microbial diversity changes. The microbiome of the infants’ 
incubators showed typical environmental bacteria. There were no significant 
differences between the incubators of septic or non-septic infants. 
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6 DISCUSSION 
 
All studies of this doctoral dissertation were to our knowledge first original 
publications concerning the cutaneous microbiome in the investigated patient 
groups: melanoma and benign melanocytic nevi, parapsoriasis and in preterm 
very low birth weight infants during the first postnatal weeks of life. In studies 
I and II the main goal was to characterize the skin surface microbiome in 
malignant, premalignant and inflammatory skin changes. The investigated 
diseases were considered to be appropriate representatives of cutaneous 
malignant (melanoma) and benign proliferation (melanocytic nevi) and of a 
chronic inflammatory disorder with potential to progress into malignancy 
(parapsoriasis). Apart of the possible novel pathogenetic insights microbiome 
studies would give to our understanding of these disorders, we were also 
interested whether non-invasive skin swab techniques could offer the 
potential to be used as new diagnostic tools in the investigated skin diseases. 
Study I is, to our knowledge, the first microbiome study about skin 
malignancies in general, and melanocytic nevi. Consequently, there was no 
former microbiome data to compare our results to. Microbiome studies have 
been performed in other non-cutaneous malignant diseases, e.g, 
gastrointestinal and oral cancer, where results have shown possible 
association of the malignant proliferation to microbiome changes and a 
bacterial dysbiosis (Singh et al. 2017, Li et al. 2014). Based on reports about a 
possible association of cancer and the microbiome, it has been under 
discussion whether the microbiome changes are epiphenomena or play a 
concrete role in the pathogenesis of the malignant transformation (Yu et al. 
2015, Dmitrieva et al. 2017). We decided to investigate the microbiome in skin 
cancer under the premise that analogously the malignant cutaneous changes 
would have an impact on the skin microbiome. The skin microbiome has been 
previously investigated mainly in chronic inflammatory skin diseases, 
specifically atopic dermatitis, psoriasis and more recently acne (Malik et al. 
2017, Langan et al. 2017, Kelhälä et al. 2018). Studies on inflammatory skin 
diseases have shown, that the underlying inflammation of the skin has 
profound effects on the surface microbiome and also some disease-
characteristic changes have been reported (Langan et al. 2017, Gonzalez et al. 
2017). Chronic inflammation has been linked to malignant transformation in 
a wide range of organ systems (Chen et al. 2017, Sfanos et al. 2017). There have 
been reports that show, that the microbiome of the gut and the intestine 
influence cancer risk by promoting chronic inflammation (Oke et al. 2017, 
Arthur et al. 2012, Yu et al. 2015). Under the rationale, that a chronic 
inflammatory state or malignant proliferation of the skin would induce 
microbiome changes, we hoped to gain more insights into the pathogenesis of 
the investigated skin disorders. Whereas melanoma and melanocytic nevi 
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were considered representatives for malignant and benign proliferation, 
respectively, and parapsoriasis was chosen to represent a chronic 
inflammatory condition with potential to malignant transformation. 
Contrary to our expectations, the microbiome data of the disorders 
investigated in studies I and II seemed to have minimal or no effects on the 
surface microbiome. The observed changes were not statistically significant. 
Altogether the skin microbiome was similar to the results of previous studies 
on healthy skin (Baviera et al. 2014, Dréno et al. 2016). We also observed a 
notable variation according to body site and individual patient (Costello et al. 
2009, Grice et al. 2009). Our results suggest accordingly, that in melanoma, 
melanocytic nevi and parapsoriasis, the skin surface microbiome on the 
investigated lesions (i.e. directly over the melanoma or parapsoriasis skin) 
does not differ from the same patient’s normal healthy skin, even though the 
investigated skin disorders have strong components of malignant proliferation 
(melanoma) and inflammation (parapsoriasis) in their pathogenesis 
(Mignonga et al. 2017, Sibbald et al. 2016). In study I, it was intended to 
concentrate on investigating the impact of malignant and benign proliferation 
on the skin microbiome. In comparison with melanocytic nevi, the melanoma 
samples showed a decrease in microbial diversity, but the difference was not 
statistically significant. Thus, the results of our study suggest that the 
investigation of the cutaneous microbiome may not be helpful in diagnosing 
melanoma or melanocytic nevi. Additionally, the results point out, that the 
proliferation of malignant melanocytic cells in the epidermis and dermis 
seems to have no significant impact on the surface microbiome. A hypothetical 
reason why this was not the case is, that in melanoma the malignant cells are 
mainly located in the dermis and primarily do not change the skin surface. 
This is mostly the case in superficial and non-ulcerative melanomas like the 
ones investigated in our study. It could thus be possible, that in deeper and 
more infiltrative melanomas differences in the skin microbiome are 
detectable. Additionally, it is possible that melanoma induced inflammation of 
the epidermal and dermal structures was in our superficial melanomas not 
sufficient to produce detectable microbiome changes. Skin microbiome 
changes have been reported mainly in inflammatory skin diseases affecting 
primarily the epidermis (Yamazaki et al. 2017, Salava et al. 2014). Similar 
microbiome changes that have been observed in inflammatory skin disorders, 
may have been absent due to the fact that in superficial melanoma the tumor-
induced inflammation is located mainly in deeper parts of the dermis (Wick 
2016). The epidermal changes, in comparison, can be marginal and consist of 
groups of malignant cells in the deeper epidermis (Damsky et al. 2017). To 
also note, the investigated sampling areas in melanoma and nevi were 
relatively small (size of the lesions mostly < 1 cm2) and thus the amount of 
bacterial DNA was limited. Thus, low bacterial DNA amounts could also have 
had an effect on the results of the microbiome data. 
To our knowledge, study II is the first publication about the skin 
microbiome in parapsoriasis and cutaneous lymphoproliferative diseases. The 
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objective was to investigate skin microbiome changes in a skin disorder with a 
chronic inflammatory pathogenesis and a potential for malignant 
transformation into cutaneous T-cell lymphoma. Here, similarly to study I, we 
did not find statistically significant differences in the skin microbiome 
between lesional parapsoriasis and control skin. Similar to the results of study 
I, it seems that the inflammation in parapsoriasis, which is located primarily 
in the dermis, leaves the surface microbiome unaffected from microbiome 
changes. Immunological factors have been reported to strongly influence the 
cutaneous microbiome and therefore we expected changes to be visible in 
parapsoriasis (Egert et al. 2017). The cutaneous microbiome in the patients of 
study II was however comparable to previous studies on healthy skin (Egert 
et al. 2016, Oh et al. 2014, Dréno et al. 2016). Studies on inflammatory skin 
disorders have shown marked, and partly specific changes in the skin 
microbiome (Yamazaki et al. 2017, Bjerre et al. 2017). The role of 
staphylococci has been particularly under investigation and there have been 
reports of S. aureus colonization during flares in atopic dermatitis (Kobayashi 
et al. 2015, Bjerre et al. 2017). Based on these recent reports we expected to 
see likewise in parapsoriasis similar or at least detectable changes in the 
surface microbiome. In study II we could however not detect specific 
cutaneous bacteria associated with parapsoriasis. The chronic, T-cell 
dominated inflammation of parapsoriasis did not show to alter the cutaneous 
bacterial communities on lesional skin. 
Parapsoriasis is regarded as a part of the continuum of lymphoproliferative 
diseases of the skin (Baderca et al. 2014). It has been observed that 
parapsoriasis and cutaneous T-cell lymphomas are strongly influenced by 
immunological factors (Rubio-Gonzalez et al. 2017). The possible association 
to dysfunctions in the immune system was another reason, why we expected 
to identify microbiome changes in parapsoriasis (Krejsgaard et al. 2017). Also 
in view of the previously demonstrated associations of the microbiome and 
cutaneous immune defense (Grice et al. 2011, Belkaid et al. 2014, 2016), we 
expected that the skin microbiome of the lesional parapsoriasis skin would 
differ from that of the same patient’s normal healthy skin (Zeeuwen et al. 
2013). A possible reason why the microbiome data of study II showed no 
significant changes is the character of the T-cell infiltrate of parapsoriasis, 
which is different from inflammatory skin disorders (Väkevä et al. 2005). 
Additionally there is an intact epidermal barrier in parapsoriasis, whereas in 
inflammatory skin disorders, such as atopic dermatitis the barrier is disrupted. 
The T-cell infiltration in parapsoriasis is mainly located in the dermis, and the 
epidermis contains only a limited amount of atypical T-lymphocytes (Sibbald 
et al. 2016, Väkevä et al 2005). This is demonstrated in figure 4, page 23, and 
figure 5, page 24 (histopathology of normal skin and parapsoriasis). Similarly 
to the results of study I, the microbiome could have remained unaffected 
because relevant pathogenetic changes take place in deeper structures of the 
skin. The stratum corneum is known to remain mainly unaffected in 
parapsoriasis, which differentiates the disease from the formerly studied skin 
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disorders, where microbiome changes have been demonstrated (Marrs et al. 
2016). Microbiome studies of inflammatory skin disorders have been most 
widely conducted in atopic dermatitis (Gonzalez et al. 2017). The pathogenesis 
of the disease is believed to be strongly influenced by the host’s immune 
response and immunological factors (e.g. the Th2-shift). Changes in the 
balance of the microbiome and the host’s cutaneous immune response have 
been shown to aggravate atopic dermatitis (Yamazaki et al. 2017). A 
colonization of the skin with staphylococci (mostly S. aureus) and profound 
changes of the skin microbiome especially during disease flares have been 
reported (Iwamoto et al. 2017). From our perspective, parapsoriasis was an 
ideal condition to expand the knowledge about the skin microbiome in 
inflammatory skin diseases. Parapsoriasis is a disorder combining 
inflammatory changes and possible malignant proliferation. Thus, we 
expected similar microbiome changes as reported in e.g. atopic dermatitis to 
be present also in parapsoriasis or at least some detectable alteration of the 
skin microbiome. 
There have been reports that Staphylococcus enterotoxins (SAE) could be 
associated with the immunological dysregulation that is caused by cutaneous 
T-cell lymphoma (Willerslev-Olsen et al. 2016, 2013). It was shown that 
Staphylococcal enterotoxin A (SEA) from the affected skin of CTCL patients 
induced in vitro IL-17 production in primary malignant T-cells of Sezary 
syndrome patients when cocultured with autologous nonmalignant T-cells 
(but not in monocultures of malignant T cells) (Willerslev-Olsen et al. 2016). 
The patients of this study were however not defined in more detail. It is also 
noteworthy that in these studies (Willerslev-Olsen et al. 2016, 2013), no 
microbes from healthy skin areas of the CTCL patients were analyzed and the 
authors did not specify the subtype of CTCL the patients were suffering from. 
Based on these observations we consequently decided to further investigate 
the staphylococcus sequences using oligotyping (Eren et al. 2013). 
Parapsoriasis is known to precede mycosis fungoides, the most common form 
of CTCL, and we targeted this study to investigate whether the chronic 
parapsoriasis lesions would have a different skin surface microbiome 
compared to the individual’s healthy (nonlesional) skin sites. The role of 
staphylococci has, to our knowledge, not been formerly investigated in 
parapsoriasis. Because of the fact that parapsoriasis is a lymphoproliferative 
disorder and often precedes cutaneous T-cell lymphoma (Cerroni 2017, 
Väkevä et al. 2005), we expected to see changes in the skin microbiome. S. 
aureus was however not identified in the microbiome data of study II. The 
results suggest that the role of S. aureus or its enterotoxins seem not to be 
relevant in parapsoriasis. This could be explained by specific differences 
between cutaneous T-cell lymphoma and parapsoriasis (T-cell infiltrate, 
localized and systemic disease), but also the metabolomics properties of the 
skin microbiome (Brandwein et al. 2016). It is also possible that unknown 
confounders explain our observations and therefore more studies regarding 
the role of the skin microbiome in parapsoriasis and cutaneous lymphomas 
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are needed. In future studies if changes in the microbiome in patients with T-
cell lymphoma are reproduced, studying large plaque parapsoriasis would be 
reasonable to associate changes with disease progression as diagnostic tool. 
In study III we targeted to characterize the cutaneous microbiome in 
preterm very low birth weight infants. Additionally, based on microbiome 
research methods we wanted to explore the possible link between skin 
staphylococcal colonization and neonatal sepsis. Study III is to our knowledge 
the first investigation of the skin microbiome during the first days of life in 
very low birth weight infants and in intensive care. Microbiome studies have 
been carried out in low birth weight neonates (Pammi et al. 2017, Costello et 
al. 2013) and the characteristics of the early cutaneous microbiome in healthy 
infants have been described recently (Capone et al. 2011, Bokulich et al. 2016). 
We observed in our patient group a high cutaneous microbial diversity during 
the first days of life regardless of the way of delivery, prematurity causes or 
perinatal infections. In this regard our results differ from recent reports 
(Garite et al. 2017, Dominquez-Bello et al. 2016, Pammi et al. 2017), where 
antibiotics, birth mode and diet were shown to influence the microbiome. 
Possible reasons could have been differences in the intensive care treatment 
and use of antibiotics, routine administration of prophylactic antibiotics and 
skin-to-skin care and feeding habits and possibilities in the intensive care 
ward. In our patient group bacterial diversity decreased during the first weeks 
of life independently from diagnosed infections or sepsis. The reasons for this 
remain unclear, but one possible explanation could be the antibiotic treatment 
in intensive care which is known to be effective against most of the skin 
colonizing bacteria (Underwood et. al. 2017, Grice et al. 2008).  Especially the 
primary antibiotics, which are given to most preterm infants in intensive care 
(and were also given to the patients of study III) are known to have high 
antimicrobial activity against the most bacteria that colonize normal skin 
(Sweeney et al. 2017, Butin et al. 2017). 
Coagulase-negative staphylococci, particularly S. epidermidis, are now 
regarded as the major pathogens in neonatal sepsis (Shane et al. 2017, Li et al. 
2013). It has remained unclear which factors change them from a member of 
the colonizing bacterial community to pathogens (Tsai et al. 2014). Disruption 
of the skin barrier by medical devices (e.g. venous catheters) and antibiotic 
treatment have been suggested to initiate these changes (Bokulich et al. 2013). 
Invasive medical devices could act as an infection port to commensal skin 
bacteria, whereas antibiotic treatment could cause a selection of virulent 
strains and suppress non-pathogenic bacteria (Bradford et al. 2011). Other 
causes that might influence the microbiome are the infants’ cutaneous 
prematurity or environmental factors (intensive care, incubator, mothers’ 
skin) (Chu et al. 2017, Power Coombs et al. 2013). It has been shown that 
cutaneous microbial diversity is positively correlated with skin-to-skin care 
and gestational age (Pammi et al. 2017). Similarly to reports on inflammatory 
skin disorders with disruption and dysfunction of the epidermal barrier (Byrd 
et al. 2017), it could be postulated that the epidermal prematurity of the 
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preterm infants has led to the detected microbiome changes (e.g. loss in 
diversity, staphylococcal domination). In study III, there was no association 
observed between microbial changes and septic infections in the intensive care 
ward. The microbiome was similar in infants with and without a diagnosed 
sepsis. Sepsis treatment with antibiotics showed no time-based association 
with the decrease in microbial diversity. Our results suggest that other factors, 
such as invasive medical devices and concomitant infections (e.g. 
gastrointestinal infections) are possible causes (Shane et al. 2017, Giomerzis 
et al. 2014). In some studies neonatal sepsis has been linked to biofilm-
associated catheter infections (Cheung et al. 2010). All patients in the study 
had a central venous line and were treated according to intensive care 
guidelines, but there were no clinically detected catheter infections described. 
There have also been reports of the association of intestinal microbiome and 
neonatal sepsis (Madan et al. 2012, Groer et al. 2015). We did not investigate 
this in study III, but the skin-intestine axis and its possible links will be 
interesting and possible research topics in future microbiome studies. 
6.1 LIMITATIONS AND CHALLENGES 
 
In studies I-II the microbiome in lesional and control skin sites were very 
similar, suggesting that the contralateral body sites did not vary from the skin 
lesions. However, it is possible that the approaches used in these studies were 
not suitable for detecting differences. Additionally, the studies were carried 
out in relatively small and heterogeneous patient cohorts and there was a 
considerable variation in the microbiome data. There were also no control 
groups used in the studies and this shortcoming was completely 
acknowledged.  
In study I an additional challenge concerned the sample collection. The 
samples were obtained from patients before the excision of the skin lesion and 
therefore histologic diagnosis of each lesion as a melanoma or a benign nevus 
was only confirmed afterwards. Consequently, controlling for subject variables 
such as age or gender was a difficult task. Skin swab sampling above the lesions 
with melanoma suspicion had to be carried out carefully because of the 
possible sampling induced superficial ulceration. In cutaneous melanoma, 
ulceration is known to be an important prognostic factor (Woodcock et al. 
2017). In addition, due to the small lesion size, the sampling areas in 
melanoma and nevi were small in comparison to studies II and III (size of the 
lesions mostly < 1 cm2). Here, the low amount of bacterial DNA could have 
affected the microbiome data.  
Study II was undertaken to investigate the skin microbiome in 
parapsoriasis skin lesions and contralateral nonlesional skin from the same 
patients. Firstly, the approach to use the patient’s healthy contralateral body 
sites as control was chosen, because it is known that there is great 
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interindividual variation in the microbiome of healthy skin and that the skin 
location is more important than ethnicity (Ursell et al. 2012, Dréno B, et al. 
2016, Perez Perez G et al. 2016). Secondly, the patients were by this time 
already diagnosed with parapsoriasis and our object was to investigate 
whether skin swab specimens could provide supplementary information to 
biopsy taking. This could have possibly decreased the need in patient follow 
up. It could have clinical consequences in the future, due to the fact that 
successive skin biopsies are often needed in the follow up of parapsoriasis 
(Bordignon et al. 2011).  
In study III, recognized limitations were a small patient cohort and 
irregularly carried out sampling during the intensive care period. A clinical 
setting such as this, made only a case study possible. Alterations of the 
guidelines in treatment (e.g. antibiotics) and patient handling (e.g. skin-to-
skin care, feeding habits) would have been unethical. 
There were many challenges encountered in the studies during sampling. 
Here the main problems concerned the standardization of skin swab sampling 
and choosing the different sampling sites. We recognize the microbiome 
sample analysis also as a challenge, especially the effects of contamination and 
the low quantities of bacterial DNA. The problem of contamination in skin 
microbiome studies has been identified frequently in the literature (Kong et 
al. 2017, Salter et al. 2014). It has been shown that DNA extraction kits can be 
an important source of contamination (Salter et al. 2014). Other potential 
sources are the reagents used in the work-flow and the laboratory personnel 
handling the samples. Even though negative controls (kit controls, PCR 
blanks) were sequenced in studies I-III, the removal of the contaminants may 
not have been enough to neutralize the contamination. It could have also been 
possible, that during the statistical approach some taxa of the original samples, 
which were not actual contaminants, were falsely removed. 
6.2 FUTURE PERSPECTIVES 
 
A new understanding of the cutaneous microbiome in skin disorders is 
developing (Oh et al. 2016). Recent microbiome studies have suggested that 
inflammatory skin disorders could at least partially be connected to a dysbiosis 
of the microbial community (Egert et al. 2016, SanMiguel et al. 2015). 
Importantly, several recent and as yet unpublished microbiome studies point 
to the fact that the complex metabolic properties of the microbiome are 
apparently more important than the microbiome profile as such (Blum 2017). 
The metabolomics of the strains of the same bacterial species may vary 
(Brandwein et al. 2016, Blum 2017). It would be important to consider 
metabolomics in future investigations of the cutaneous microbiome in skin 
diseases. Regarding the investigation of the microbiome of malignant skin 
changes it would be interesting to investigate the cutaneous microbiome in 
 47 
deeper melanomas and to examine if recognized melanoma risk factors (family 
history, multiple or dysplastic nevi) have an effect on the microbiome (Hawkes 
et al. 2016). It would also be important to investigate the microbiome in 
ulcerated melanomas and whether in these cases the microbiome data differs 
from our observations. 
Microbiome studies are evolving also as an interesting novel method in 
research of inflammatory skin diseases. In some inflammatory skin disorders 
the reported microbiome changes have been relatively characteristic (Langan 
et al. 2017). Therefore they might be useful in diagnosis, e.g. complementary 
to histopathology (Powers et al. 2015). As a future perspective, exploring the 
microbiome might answer pathogenetic questions and have a role in 
diagnostics and treatments (Kong et al. 2017, Sharon et al. 2014, Zeeuwen et 
al. 2013). Regardless of the results of study II, in the course of parapsoriasis a 
change of the skin microbiome is possible, as this is seen in inflammatory skin 
disorders like atopic dermatitis (Bjerre et al. 2017, Shi et al. 2016, Gonzalez et 
al. 2017). Microbiome studies could possibly answer some aspects of the 
pathogenesis of parapsoriasis and in the future lead to new diagnostic 
methods. Therefore it would be important to further explore how the 
microbiome changes during the progression of the disease (Talpur et al. 2017). 
Furthermore, it would also be interesting to investigate the microbiome in 
those parapsoriasis patients, where the disease has already developed into 
cutaneous lymphoma (Eklund et al. 2016). 
Microbiome studies have not been conducted largely in neonates and this 
field of microbiome research is just beginning. We recognize its potential and 
perhaps future studies will determine the role of the cutaneous microbiome in 
early skin development and investigate whether there are possible links 
between skin microbiome changes and developmental or other clinical 
complications. Comparable to the reported longitudinal differences in the 
fecal microbiome (Aujoulat et al. 2014, Singh et al. 2017), it would be 
interesting to further explore how in preterm neonates the cutaneous 
microbiome changes during early life and whether microbiome changes are 
linked to problems in early development. 
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7 CONCLUSIONS 
Study I 
 
The microbiome of melanomas and melanocytic nevi was similar to healthy 
skin. There was a notable variation based on body site and individual patient, 
which suggests that microbiome studies may not be helpful in diagnosing 
melanoma or melanocytic nevi. Melanoma samples showed a decreased 
microbial diversity when compared to melanocytic nevi, but this difference 
was not statistically significant. It would be important to investigate the 
microbiome in deeper or ulcerated melanomas and explore if melanoma risk 
factors alter the microbiome.  
 
Study II 
 
No differences were found between the microbiome of parapsoriasis and the 
same patients’ healthy skin. This suggest that there are no specific associations 
of cutaneous bacteria, and parapsoriasis does not alter the microbiome of 
human skin. The role of S. aureus seems not to be relevant in parapsoriasis. It 
would be important to explore microbiome changes during progression of the 
disease and to investigate the microbiome in cutaneous lymphomas. 
 
Study III 
 
Very low birth weight infants in intensive care showed a high cutaneous 
microbial diversity during the first days of life regardless of the way of delivery, 
prematurity causes or perinatal infections. Microbial diversity decreased 
during first weeks of life independently from sepsis or antibiotic treatment. 
Other factors such as invasive medical devices are likely to play a role here. It 
would be important to further explore how the cutaneous microbiome changes 
during early life and whether microbiome changes are linked to problems in 
development. 
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